Edap Tms (NASDAQ:EDAP) & Artivion (NYSE:AORT) Head-To-Head Review

Edap Tms (NASDAQ:EDAP) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Profitability

This table compares Edap Tms and Artivion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edap Tms	-41.47%	-137.61%	-40.62%
Artivion	2.55%	7.15%	3.63%

Analyst Ratings

This is a breakdown of current ratings for Edap Tms and Artivion, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edap Tms	1	1	1	0	2.00
Artivion	0	1	7	0	2.88

Edap Tms presently has a consensus price target of $6.00, suggesting a potential upside of 39.53%. Artivion has a consensus price target of $47.83, suggesting a potential upside of 113.09%. Given Artivion’s stronger consensus rating and higher possible upside, analysts clearly believe Artivion is more favorable than Edap Tms.

Valuation and Earnings

This table compares Edap Tms and Artivion”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edap Tms	$74.07 million	2.18	-$29.25 million	($0.81)	-5.31
Artivion	$441.33 million	2.47	$9.77 million	$0.24	93.53

Artivion has higher revenue and earnings than Edap Tms. Edap Tms is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

62.7% of Edap Tms shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 0.2% of Edap Tms shares are held by company insiders. Comparatively, 6.3% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Edap Tms has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Summary

Artivion beats Edap Tms on 14 of the 14 factors compared between the two stocks.

About Edap Tms

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

About Artivion

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.